QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
BRCA1 and BRCA2 were identified in the 1990s as the causative genes underlying hereditary breast and ovarian cancer syndrome with genetic testing beginning during the same decade for treatment of patients and their relatives. The target BRCA1 and BRCA 2…
This issue of Quest features our Secretary-Treasurer, Jim Rothkopf, who has lived on the East Coast his entire life. Born in Brooklyn, he attended New York University for his undergraduate degree and received his M.B.A. degree from the American University…
The authors conducted a retrospective review of patients who developed spread of cancer cells throughout the abdomen (called “peritoneal carcinomatosis”) following robot-assisted radical prostatectomy. Five cases were identified. The patients developed the disease between 8 and 13 years after the…
A report in JAMA (Journal of American Medicine) shows that there is a significant mortality benefit to those walking at least 7000 steps per day. In the study of more than 2000 Black and White adults, participants taking at least…
After radical prostatectomy, in men with still detectable PSA levels, administering salvage radiation therapy to the prostate bed results in about 70% of patients being free of progression at 5 years. A three-group randomized trial was designed to determine…
Researchers assessed the diagnostic estimates of serial prostate MRI scans for detecting prostate cancer progression during active surveillance for low-risk prostate cancer. Systematically searching the scientific publication databases, they selected 15 studies for review, a total of 2240 patients. The…
Incorporating genetic factors that influence PSA levels into prostate cancer screening may help reduce unnecessary invasive testing and improve the detection of aggressive disease. “We know from previous research that PSA levels are highly heritable (30-40%)—so we know that genetic…
This retrospective study examined the effect of continuing active surveillance (AS) on the oncological outcomes in 531 patients on AS for prostate cancer (grade group 1; PSA level 20 mg/mL) who were subsequently upgraded to ≥GG2, and underwent further surveillance…
A nomogram has been developed to predict PSMA-PET scan results for recurrent prostate cancer. Medical nomograms use biologic and clinical variables, such as tumor grade and patient age to graphically depict a statistical predictive model that generates a probability of…
This retrospective analysis investigated whether the use of metformin and statins improve the overall survival and PSA response rate in men receiving abiraterone acetate plus prednisone/prednisolone (AAP) for metastatic castration-resistant prostate cancer (mCRPC) either before or after chemotherapy. The use…
"*" indicates required fields
